Associated Genetic Biomarkers
MDC1 is altered in 1.75% of all cancers with lung adenocarcinoma, cutaneous melanoma, colon adenocarcinoma, breast invasive ductal carcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in MDC1 are MDC1 Mutation (1.00%), MDC1 Amplification (0.11%), MDC1 Deletion (0.01%), MDC1 Loss (0.01%), and MDC1 D929N (0.01%) .
MDC1 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain MDC1 status as an inclusion criterion, 2 are phase 2 (2 open).
Trials with MDC1 status in the inclusion eligibility criteria most commonly target melanoma and urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is MDC1 Mutation .
Nivolumab, olaparib, and talazoparib are the most frequent therapies in trials with MDC1 as an inclusion criteria .
Significance of MDC1 in Diseases
Urothelial Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.